Shopping Cart 0
Cart Subtotal
AED 0

bluebird bio Inc (BLUE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753

Details

Summary

Bluebird Bio Inc (bluebird bio) is a clinical stage biotechnology company that focuses on the development of new gene therapies for the treatment of severe genetic diseases and cancer. The company develops its products based on integrated product platforms such as gene therapy, cancer immunotherapy and gene editing. Its product pipeline includes Lenti D for the treatment of cerebral adrenoleukodystrophy (CALD); LentiGlobin for the treatment of transfusion-dependent beta thalassemia and sickle cell disease, besides compounds under development for the treatment of various cancers. The company has collaboration with various pharmaceutical companies to discover, develop and commercialize gene therapy products to treat cancer. bluebird bio is headquartered in Cambridge, Massachusetts, the US.

bluebird bio Inc (BLUE)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

bluebird bio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

bluebird bio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

bluebird bio Inc, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

bluebird bio Raises USD 60 Million In Series D Financing 12

Partnerships 14

bluebird bio and Gritstone Oncology Enter into Agreement 14

Regeneron Pharma and bluebird bio to Enter into Collaboration Agreement 15

Celgene and Bluebird Enter into Co-Development Agreement 16

Kite Pharma Enters into Co-Development Agreement with Bluebird bio 17

bluebird bio Amends Co-Development Agreement With Celgene 18

Licensing Agreements 19

bluebird bio Enters into Licensing Agreement with TC BioPharm 19

GlaxoSmithKline Intellectual Property Development Enters into Licensing Agreement with bluebird bio 20

Novartis Pharma Enters into Licensing Agreement with bluebird bio 21

MediGene Expands Licensing Agreement with bluebird bio 22

Bluebird bio Enters Into Licensing Agreement With ViroMed 23

bluebird bio Enters into Licensing Agreement with National Institutes of Health 24

bluebird bio Enters into Licensing Agreement with Biogen 25

Celgene Exercises its Option to Exclusively License bb21217 with bluebird bio 26

Equity Offering 27

bluebird bio Raises USD632.5 Million in Public Offering of Shares 27

bluebird bio Raises USD651.3 Million in Public Offering of Shares 29

bluebird bio Raises USD460 Million in Public Offering of Shares 31

bluebird bio Raises USD250 Million in Public Offering of Shares 33

Bluebird bio Raises USD500 Million in Public Offering of Shares 35

Bluebird bio Raises USD259 Million in Public Offering of Shares 37

Bluebird bio Raises USD117.3 Million in Public Offering of Shares 39

bluebird bio Completes IPO For USD 116 Million 41

Acquisition 43

Bluebird bio Acquires Precision Genome Engineering 43

bluebird bio Inc-Key Competitors 44

bluebird bio Inc-Key Employees 45

bluebird bio Inc-Locations And Subsidiaries 46

Head Office 46

Other Locations & Subsidiaries 46

Recent Developments 47

Financial Announcements 47

Nov 01, 2018: bluebird bio reports third quarter 2018 financial results and highlights operational progress 47

Aug 02, 2018: bluebird bio reports second quarter 2018 financial results and highlights operational progress 50

May 02, 2018: bluebird bio Announces First Quarter 2018 Financial Results 53

Feb 21, 2018: bluebird bio Announces Fourth Quarter and Full Year 2017 Financial Results 54

Nov 01, 2017: bluebird bio Reports Third Quarter 2017 Financial Results and Recent Operational Progress 56

Aug 02, 2017: bluebird bio Reports Second Quarter 2017 Financial Results and Recent Operational Progress 58

May 03, 2017: bluebird bio Reports First Quarter 2017 Financial Results and Recent Operational Progress 60

Feb 22, 2017: bluebird bio Reports Fourth Quarter and Full Year 2016 Financial Results and Recent Operational Progress 61

Corporate Communications 63

Feb 14, 2018: bluebird bio Names Alison Finger As Chief Commercial Officer 63

Sep 20, 2017: bluebird bio Appoints Mary Lynne Hedley, Ph.D. to Board of Directors 64

Jun 08, 2017: bluebird bio Appoints John O. Agwunobi, M.D. and Douglas A. Melton, Ph.D. to Board of Directors 65

Product News 66

12/11/2017: bluebird bio Presents Updated Data from HGB-205 Study of LentiGlobin Gene Therapy in Patients with Severe Sickle Cell Disease and Transfusion-Dependent -Thalassemia at American Society of Hematology Annual Meeting 66

10/04/2017: bluebird bio Announces Publication of Interim Data from Starbeam Study of Lenti-DTM Drug Product in Patients with Cerebral Adrenoleukodystrophy (CALD) in The New England Journal of Medicine 68

10/04/2017: Gene therapy halts progression of childhood cerebral adrenoleukodystrophy in clinical trial 70

09/06/2017: bluebird bio to Present Interim Clinical Data from Starbeam Study of Lenti-DTM Drug Product in Cerebral Adrenoleukodystrophy at Child Neurology Society 2017 Annual Meeting 72

06/26/2017: bluebird bio Announces Topline Interim Clinical Data from Starbeam Study of Lenti-D Drug Product in Cerebral Adrenoleukodystrophy 73

06/23/2017: bluebird bio Presents New Data from HGB-205 Study of LentiGlobin Drug Product in Patients with Transfusion-Dependent -Thalassemia and Severe Sickle Cell Disease at European Hematology Association Annual Meeting 74

06/15/2018: bluebird bio Presents New Data from Northstar (HGB-204) and Northstar-2 (HGB-207) Studies of LentiGlobin Gene Therapy in Patients with Transfusion-Dependent -Thalassemia at Annual Congress of the European Hematology Association 76

04/18/2018: bluebird bio Announces New England Journal of Medicine Publication of Interim Data from Two Phase 1/2 Clinical Studies of LentiGlobin Gene Therapy in Patients with Transfusion-Dependent -Thalassemia 78

03/01/2017: bluebird bio Announces Publication of Case Study on First Patient with Severe Sickle Cell Disease Treated with Gene Therapy in The New England Journal of Medicine 80

01/31/2018: Sickle cell gene therapy to boost fetal hemoglobin: A 70-year timeline of discovery 81

Clinical Trials 82

Jun 15, 2018: bluebird bio Announces New Interim Data from Phase 1 (HGB-206) Study of LentiGlobin Gene Therapy in Patients with Severe Sickle Cell Disease at Annual Congress of the European Hematology Association 82

May 17, 2018: bluebird bio to Present New Data from LentiGlobin Transfusion-Dependent -Thalassemia and Severe Sickle Cell Disease Clinical Studies at Annual Congress of the European Hematology Association 84

Dec 10, 2017: bluebird bio Presents New Data from Clinical Studies of LentiGlobin Gene Therapy in Transfusion-Dependent -Thalassemia at American Society of Hematology Annual Meeting 86

Nov 16, 2017: bluebird bio Announces First Patient Treated in Northstar-3 (HGB-212), Phase 3 Study of LentiGlobin in Patients with Transfusion-Dependent -Thalassemia (TDT) and 0/0 Genotype 88

Nov 01, 2017: bluebird bio to Present New Data from Clinical Studies of LentiGlobin Gene Therapy in Transfusion-Dependent -Thalassemia at ASH Annual Meeting 89

Sep 28, 2017: bluebird bio Announces First Patient Treated with Second Anti-BCMA CAR T bb21217 in CRB-402 Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma 92

Jun 23, 2017: bluebird bio Announces Early Data from Phase 3 Northstar-2 (HGB-207) Study of LentiGlobin Drug Product at European Hematology Association (EHA) Annual Meeting 93

May 18, 2017: bluebird bio to Present New Data from LentiGlobin Clinical Studies at European Hematology Association Annual Meeting 94

Feb 03, 2017: bluebird bio Announces First Patient Treated with LentiGlobin Drug Product Under Amended Study Protocol in HGB-206 Phase 1 Study of Patients with Severe Sickle Cell Disease 95

Other Significant Developments 96

Feb 14, 2018: The Alliance for Regenerative Medicine Announces Initial Slate of Presenting Companies at the Sixth Annual Cell & Gene Therapy Investor Day 96

Appendix 97

Methodology 97

About GlobalData 97

Contact Us 97

Disclaimer 97


List Of Figure

List of Figures

bluebird bio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

bluebird bio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

bluebird bio Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

bluebird bio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

bluebird bio Inc, Deals By Therapy Area, 2012 to YTD 2018 9

bluebird bio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

bluebird bio Raises USD 60 Million In Series D Financing 12

bluebird bio and Gritstone Oncology Enter into Agreement 14

Regeneron Pharma and bluebird bio to Enter into Collaboration Agreement 15

Celgene and Bluebird Enter into Co-Development Agreement 16

Kite Pharma Enters into Co-Development Agreement with Bluebird bio 17

bluebird bio Amends Co-Development Agreement With Celgene 18

bluebird bio Enters into Licensing Agreement with TC BioPharm 19

GlaxoSmithKline Intellectual Property Development Enters into Licensing Agreement with bluebird bio 20

Novartis Pharma Enters into Licensing Agreement with bluebird bio 21

MediGene Expands Licensing Agreement with bluebird bio 22

Bluebird bio Enters Into Licensing Agreement With ViroMed 23

bluebird bio Enters into Licensing Agreement with National Institutes of Health 24

bluebird bio Enters into Licensing Agreement with Biogen 25

Celgene Exercises its Option to Exclusively License bb21217 with bluebird bio 26

bluebird bio Raises USD632.5 Million in Public Offering of Shares 27

bluebird bio Raises USD651.3 Million in Public Offering of Shares 29

bluebird bio Raises USD460 Million in Public Offering of Shares 31

bluebird bio Raises USD250 Million in Public Offering of Shares 33

Bluebird bio Raises USD500 Million in Public Offering of Shares 35

Bluebird bio Raises USD259 Million in Public Offering of Shares 37

Bluebird bio Raises USD117.3 Million in Public Offering of Shares 39

bluebird bio Completes IPO For USD 116 Million 41

Bluebird bio Acquires Precision Genome Engineering 43

bluebird bio Inc, Key Competitors 44

bluebird bio Inc, Key Employees 45

bluebird bio Inc, Other Locations 46

bluebird bio Inc, Subsidiaries 46

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

bluebird bio Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Bluebird Bio Inc (bluebird bio) is a clinical stage biotechnology company that focuses on the development of new gene therapies for the treatment of severe genetic diseases and cancer. The company develops its products based on integrated product platforms such as gene therapy, cancer immunotherapy and gene editing. Its product pipeline includes Lenti D for the treatment of cerebral adrenoleukodystrophy (CALD); LentiGlobin for the treatment of transfusion-dependent beta thalassemia and sickle cell disease, besides compounds under development for the treatment of various cancers. The company has collaboration with various pharmaceutical companies to discover, develop and commercialize gene therapy products to treat cancer. bluebird bio is headquartered in Cambridge, Massachusetts, the US.

bluebird bio Inc (BLUE)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

bluebird bio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

bluebird bio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

bluebird bio Inc, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

bluebird bio Raises USD 60 Million In Series D Financing 12

Partnerships 14

bluebird bio and Gritstone Oncology Enter into Agreement 14

Regeneron Pharma and bluebird bio to Enter into Collaboration Agreement 15

Celgene and Bluebird Enter into Co-Development Agreement 16

Kite Pharma Enters into Co-Development Agreement with Bluebird bio 17

bluebird bio Amends Co-Development Agreement With Celgene 18

Licensing Agreements 19

bluebird bio Enters into Licensing Agreement with TC BioPharm 19

GlaxoSmithKline Intellectual Property Development Enters into Licensing Agreement with bluebird bio 20

Novartis Pharma Enters into Licensing Agreement with bluebird bio 21

MediGene Expands Licensing Agreement with bluebird bio 22

Bluebird bio Enters Into Licensing Agreement With ViroMed 23

bluebird bio Enters into Licensing Agreement with National Institutes of Health 24

bluebird bio Enters into Licensing Agreement with Biogen 25

Celgene Exercises its Option to Exclusively License bb21217 with bluebird bio 26

Equity Offering 27

bluebird bio Raises USD632.5 Million in Public Offering of Shares 27

bluebird bio Raises USD651.3 Million in Public Offering of Shares 29

bluebird bio Raises USD460 Million in Public Offering of Shares 31

bluebird bio Raises USD250 Million in Public Offering of Shares 33

Bluebird bio Raises USD500 Million in Public Offering of Shares 35

Bluebird bio Raises USD259 Million in Public Offering of Shares 37

Bluebird bio Raises USD117.3 Million in Public Offering of Shares 39

bluebird bio Completes IPO For USD 116 Million 41

Acquisition 43

Bluebird bio Acquires Precision Genome Engineering 43

bluebird bio Inc-Key Competitors 44

bluebird bio Inc-Key Employees 45

bluebird bio Inc-Locations And Subsidiaries 46

Head Office 46

Other Locations & Subsidiaries 46

Recent Developments 47

Financial Announcements 47

Nov 01, 2018: bluebird bio reports third quarter 2018 financial results and highlights operational progress 47

Aug 02, 2018: bluebird bio reports second quarter 2018 financial results and highlights operational progress 50

May 02, 2018: bluebird bio Announces First Quarter 2018 Financial Results 53

Feb 21, 2018: bluebird bio Announces Fourth Quarter and Full Year 2017 Financial Results 54

Nov 01, 2017: bluebird bio Reports Third Quarter 2017 Financial Results and Recent Operational Progress 56

Aug 02, 2017: bluebird bio Reports Second Quarter 2017 Financial Results and Recent Operational Progress 58

May 03, 2017: bluebird bio Reports First Quarter 2017 Financial Results and Recent Operational Progress 60

Feb 22, 2017: bluebird bio Reports Fourth Quarter and Full Year 2016 Financial Results and Recent Operational Progress 61

Corporate Communications 63

Feb 14, 2018: bluebird bio Names Alison Finger As Chief Commercial Officer 63

Sep 20, 2017: bluebird bio Appoints Mary Lynne Hedley, Ph.D. to Board of Directors 64

Jun 08, 2017: bluebird bio Appoints John O. Agwunobi, M.D. and Douglas A. Melton, Ph.D. to Board of Directors 65

Product News 66

12/11/2017: bluebird bio Presents Updated Data from HGB-205 Study of LentiGlobin Gene Therapy in Patients with Severe Sickle Cell Disease and Transfusion-Dependent -Thalassemia at American Society of Hematology Annual Meeting 66

10/04/2017: bluebird bio Announces Publication of Interim Data from Starbeam Study of Lenti-DTM Drug Product in Patients with Cerebral Adrenoleukodystrophy (CALD) in The New England Journal of Medicine 68

10/04/2017: Gene therapy halts progression of childhood cerebral adrenoleukodystrophy in clinical trial 70

09/06/2017: bluebird bio to Present Interim Clinical Data from Starbeam Study of Lenti-DTM Drug Product in Cerebral Adrenoleukodystrophy at Child Neurology Society 2017 Annual Meeting 72

06/26/2017: bluebird bio Announces Topline Interim Clinical Data from Starbeam Study of Lenti-D Drug Product in Cerebral Adrenoleukodystrophy 73

06/23/2017: bluebird bio Presents New Data from HGB-205 Study of LentiGlobin Drug Product in Patients with Transfusion-Dependent -Thalassemia and Severe Sickle Cell Disease at European Hematology Association Annual Meeting 74

06/15/2018: bluebird bio Presents New Data from Northstar (HGB-204) and Northstar-2 (HGB-207) Studies of LentiGlobin Gene Therapy in Patients with Transfusion-Dependent -Thalassemia at Annual Congress of the European Hematology Association 76

04/18/2018: bluebird bio Announces New England Journal of Medicine Publication of Interim Data from Two Phase 1/2 Clinical Studies of LentiGlobin Gene Therapy in Patients with Transfusion-Dependent -Thalassemia 78

03/01/2017: bluebird bio Announces Publication of Case Study on First Patient with Severe Sickle Cell Disease Treated with Gene Therapy in The New England Journal of Medicine 80

01/31/2018: Sickle cell gene therapy to boost fetal hemoglobin: A 70-year timeline of discovery 81

Clinical Trials 82

Jun 15, 2018: bluebird bio Announces New Interim Data from Phase 1 (HGB-206) Study of LentiGlobin Gene Therapy in Patients with Severe Sickle Cell Disease at Annual Congress of the European Hematology Association 82

May 17, 2018: bluebird bio to Present New Data from LentiGlobin Transfusion-Dependent -Thalassemia and Severe Sickle Cell Disease Clinical Studies at Annual Congress of the European Hematology Association 84

Dec 10, 2017: bluebird bio Presents New Data from Clinical Studies of LentiGlobin Gene Therapy in Transfusion-Dependent -Thalassemia at American Society of Hematology Annual Meeting 86

Nov 16, 2017: bluebird bio Announces First Patient Treated in Northstar-3 (HGB-212), Phase 3 Study of LentiGlobin in Patients with Transfusion-Dependent -Thalassemia (TDT) and 0/0 Genotype 88

Nov 01, 2017: bluebird bio to Present New Data from Clinical Studies of LentiGlobin Gene Therapy in Transfusion-Dependent -Thalassemia at ASH Annual Meeting 89

Sep 28, 2017: bluebird bio Announces First Patient Treated with Second Anti-BCMA CAR T bb21217 in CRB-402 Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma 92

Jun 23, 2017: bluebird bio Announces Early Data from Phase 3 Northstar-2 (HGB-207) Study of LentiGlobin Drug Product at European Hematology Association (EHA) Annual Meeting 93

May 18, 2017: bluebird bio to Present New Data from LentiGlobin Clinical Studies at European Hematology Association Annual Meeting 94

Feb 03, 2017: bluebird bio Announces First Patient Treated with LentiGlobin Drug Product Under Amended Study Protocol in HGB-206 Phase 1 Study of Patients with Severe Sickle Cell Disease 95

Other Significant Developments 96

Feb 14, 2018: The Alliance for Regenerative Medicine Announces Initial Slate of Presenting Companies at the Sixth Annual Cell & Gene Therapy Investor Day 96

Appendix 97

Methodology 97

About GlobalData 97

Contact Us 97

Disclaimer 97


List Of Figure

List of Figures

bluebird bio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

bluebird bio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

bluebird bio Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

bluebird bio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

bluebird bio Inc, Deals By Therapy Area, 2012 to YTD 2018 9

bluebird bio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

bluebird bio Raises USD 60 Million In Series D Financing 12

bluebird bio and Gritstone Oncology Enter into Agreement 14

Regeneron Pharma and bluebird bio to Enter into Collaboration Agreement 15

Celgene and Bluebird Enter into Co-Development Agreement 16

Kite Pharma Enters into Co-Development Agreement with Bluebird bio 17

bluebird bio Amends Co-Development Agreement With Celgene 18

bluebird bio Enters into Licensing Agreement with TC BioPharm 19

GlaxoSmithKline Intellectual Property Development Enters into Licensing Agreement with bluebird bio 20

Novartis Pharma Enters into Licensing Agreement with bluebird bio 21

MediGene Expands Licensing Agreement with bluebird bio 22

Bluebird bio Enters Into Licensing Agreement With ViroMed 23

bluebird bio Enters into Licensing Agreement with National Institutes of Health 24

bluebird bio Enters into Licensing Agreement with Biogen 25

Celgene Exercises its Option to Exclusively License bb21217 with bluebird bio 26

bluebird bio Raises USD632.5 Million in Public Offering of Shares 27

bluebird bio Raises USD651.3 Million in Public Offering of Shares 29

bluebird bio Raises USD460 Million in Public Offering of Shares 31

bluebird bio Raises USD250 Million in Public Offering of Shares 33

Bluebird bio Raises USD500 Million in Public Offering of Shares 35

Bluebird bio Raises USD259 Million in Public Offering of Shares 37

Bluebird bio Raises USD117.3 Million in Public Offering of Shares 39

bluebird bio Completes IPO For USD 116 Million 41

Bluebird bio Acquires Precision Genome Engineering 43

bluebird bio Inc, Key Competitors 44

bluebird bio Inc, Key Employees 45

bluebird bio Inc, Other Locations 46

bluebird bio Inc, Subsidiaries 46

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

bluebird bio Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.